Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,706 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all
Completed No phase listed Observational

Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients

NCT03413696
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 17, 2026, 12:04 PM EDT
Terminated Phase 2 Interventional

A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma

NCT00020683
View directory record Official record
Conditions
AIDS-related Kaposi Sarcoma, HIV Infection
Interventions
incyclinide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 17, 2026, 12:04 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Combined Injectable Treatment for HIV and OUD

NCT05991622
View directory record Official record
Conditions
Human Immunodeficiency Virus, Opioid Use Disorder
Interventions
Combined LAI Treatment: Cabenuva and Sublocade
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 3 Interventional

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

NCT00002122
View directory record Official record
Conditions
Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin, Rifabutin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 12:04 PM EDT
Terminated Phase 4 Interventional Results available

Artery Elasticity After Switch From Epzicom to Truvada

NCT00998582
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 17, 2026, 12:04 PM EDT
Terminated Phase 1 Interventional

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

NCT06430905
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo
Biological · Other
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Orlando, Florida • Decatur, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 17, 2026, 12:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

NCT02797470
View directory record Official record
Conditions
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Melphalan, Peripheral Blood Stem Cell Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
4
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 1 Interventional

PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection

NCT00775424
View directory record Official record
Conditions
HIV Infection
Interventions
PENNVAX-B, GENEVAX IL-12-4532, PLACEBO, IL-15 adjuvant
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 2 Interventional

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

NCT00002423
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 12:04 PM EDT
Completed No phase listed Observational

Treatment of Acute HIV Infection to Preserve Immune Function

NCT00055094
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 12:04 PM EDT
Completed No phase listed Observational

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

NCT01906255
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10,577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous Dendritic Cell Vaccine in HIV1 Infection

NCT00510497
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous HIV-1 ApB DC Vaccine
Biological
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 4 Interventional Results available

Maraviroc Efficacy for Hepatitis C

NCT02881762
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
Maraviroc
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 17, 2026, 12:04 PM EDT
Completed No phase listed Observational

Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART

NCT02322827
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Human Immunodeficiency Virus Type
Interventions
Not listed
Lead sponsor
Olayemi Osiyemi MD
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

NCT02859259
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 17, 2026, 12:04 PM EDT
Terminated Not applicable Interventional

Targeting Non-virally Suppressed Adults With Alcohol Use Disorder in HIV Primary Care

NCT04280068
View directory record Official record
Conditions
Alcohol Dependence, HIV/AIDS
Interventions
Clinician Guide (CG), Clinician Guide plus HealthCall
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 2 Interventional

A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children

NCT00000913
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
33
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 17, 2026, 12:04 PM EDT
Not listed Phase 4 Interventional

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

NCT04826562
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Dolutegravir/Lamivudine
Drug
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Not applicable Interventional

Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus

NCT01760759
View directory record Official record
Conditions
HIV
Interventions
cell phone reminders, contingency management for adherence
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Farmington, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacy-based Pre-exposure Prophylaxis

NCT04393935
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Pharmacy Delivered PrEP Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 17, 2026, 12:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mental Ability Challenge Study in Adults With and Without HIV

NCT03244488
View directory record Official record
Conditions
HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex
Interventions
Scopolamine Injectable Product, Mecamylamine Pill
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
35 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 1 Interventional

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

NCT02652546
View directory record Official record
Conditions
HIV, Inflammation
Interventions
Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

NCT01498861
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Ortho-Cyclen, Dolutegravir, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 17, 2026, 12:04 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Three NNRTI-Sparing HAART Regimens

NCT00811954
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir, Ritonavir, Atazanavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
1,814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
55
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 17, 2026, 12:04 PM EDT